Price and states served both move. Read them off the seller's own site before you enroll.How our reviews work →

altRX vs Direct Meds

altRX costs $100 less a month, and both sell semaglutide and tirzepatide.

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

By Ruth Calder · Enforcement Editor
Editorially reviewed & fact-checked against primary sources · How we verify contentLast reviewed
altRX logo

altRX

6.7
★★★☆☆3.4/5

Best for: semaglutide from $1149/month

Visit altRX →
VS
Direct Meds logo

Direct Meds

6.4
★★★☆☆3.2/5

Best for: compounded semaglutide at $249/month

Visit Direct Meds →

If you are choosing between altRX and Direct Meds, the first difference is cost: altRX is $100 a month cheaper at the entry price. Both prescribe semaglutide and tirzepatide, so moving from one to the other would not change your drug. altRX leads our six-part score, 6.7 to 6.4. Both have drawn an FDA warning letter.

altRX vs Direct Meds price

altRX is the cheaper way in: $149 a month against $249 a month at Direct Meds. That is $100 less each month (40% lower), or about $1,200 over a year of treatment.

Drug by drug: Semaglutide is cheaper at altRX ($149 a month vs $249 a month); tirzepatide is cheaper at altRX ($249 a month vs $299 a month).

Medications and formats

Both sell semaglutide and tirzepatide.

On format, altRX prices compounded injections and brand-name pens, while Direct Meds prices compounded injections.

If you want the FDA-approved brand rather than a compounded version, altRX is the only one of the two with a brand-name price.

Where each one treats patients

Neither altRX nor Direct Meds publishes the states it serves, so enter your state at the very start of each sign-up.

Pricing

altRX

Compounded GLP-1 (semaglutide) starting tierCompounded
$149/mo
semaglutide
Compounded GLP-1/GIP (tirzepatide) starting tierCompounded
$249/mo
tirzepatide
Brand-name Ozempic®Brand-name
$1149/mo
semaglutide
Brand-name Mounjaro®Brand-name
$1249/mo
tirzepatide
Brand-name Zepbound®Brand-name
$1249/mo
tirzepatide
Brand-name Wegovy®Brand-name
$1579/mo
semaglutide

Direct Meds

SublingualCompounded
$249/mo
semaglutide

'As low as $249' per month, on a 90-day supply billed monthly; some doses run as low as $237/mo.

InjectionCompounded
$297/mo
semaglutide

'As low as $297' per month ($9.58 a day), an 84-day three-pack billed monthly.

SublingualCompounded
$299/mo
tirzepatide

'As low as $299' per month ($9.65 a day) on a 90-day supply billed monthly. Down from $399 earlier.

InjectionCompounded
$399/mo
tirzepatide

'As low as $399' per month ($12.87 a day).

What each price covers

Both prices cover the clinician visit, the medication itself and shipping.

altRX is silent on lab work and coaching.

Direct Meds is silent on lab work and coaching.

altRX

Covered by the monthly price

Medication

In the price

Clinician visits

In the price

Shipping

In the price

Lab work

Not stated

Coaching

Not stated

Direct Meds

Covered by the monthly price

Medication

In the price

Clinician visits

In the price

Shipping

In the price

Lab work

Not stated

Coaching

Not stated

Where each one scores higher

Overall, altRX scores 6.7 and Direct Meds 6.4 out of 10.

altRX is stronger on value (5.0 vs 3.7).

Effectiveness, user experience, trust & safety, accessibility and support are within half a point.

How we score

altRX

6.7/10

Overall

Direct Meds

6.4/10

Value25%

5.0A
vs
B
3.7

Effectiveness25%

10.0A
vs
B
10.0

User Experience15%

8.0A
vs
B
8.0

Trust & Safety15%

3.5A
vs
B
3.5

Accessibility10%

5.0A
vs
B
5.0

Support10%

7.0A
vs
B
7.0

FDA warning letters

The FDA sent altRX a warning letter dated June 8, 2026 (letter 728236), and it is still open.

The FDA sent Direct Meds a warning letter dated September 9, 2025 (letter 716822), and it is still open.

Features & Coverage

FeaturealtRXDirect Meds
Starting Price✓$149/mo$249/mo
Features✓8 features5 features
States AvailableNot disclosedNot disclosed
Compounded✓ Yes✓ Yes
Brand Name✓ Yes—
FSA/HSA Accepted——
FDA Warning Letters1 letter1 letter

About altRX

Compounded plans open at $149 for semaglutide and $249 for tirzepatide. Branded medication runs $1,149-$1,579, a figure that already contains the consult and the shipping. Every one of the four FDA-approved brands is stocked, Mounjaro, Ozempic, Wegovy and Zepbound, which no other entry in our directory matches. altRX works in both modalities, holds LegitScript certification, and prints the FDA compounded-medication disclaimer.

Read our full altRX review →

About Direct Meds

The FDA sent Direct Meds a warning letter in September 2025 over misleading marketing, and customers have reported a documented pattern of unexpected 3-month commitment charges. We list the company with both disclosed in full; read the warnings and the cons first. Its products are compounded semaglutide and tirzepatide, sold from Utah in injection and sublingual form.

Read our full Direct Meds review →

Pros & Cons

altRX

What we like

  • Tirzepatide costs $1249 a month, close to the $1249 median for brand-name tirzepatide across the sellers we compare
  • Shows its price before the medical questionnaire, so you can compare it without handing over health information
  • The monthly price includes the medication, clinician visits and shipping

Watch-outs

  • Semaglutide costs $1149 a month, 16% above the $990 median for brand-name semaglutide across the sellers we compare
  • Confirm it serves your state before you start the intake
  • Ask which pharmacy fills the prescription before you pay, so you can check its license
  • The FDA has issued altRX a warning letter. Read what it alleges: a letter flags a problem but does not by itself rule a seller out
  • Its semaglutide and tirzepatide are compounded rather than FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality

Direct Meds

What we like

  • Shows its price before the medical questionnaire, so you can compare it without handing over health information
  • The monthly price includes the medication, clinician visits and shipping

Watch-outs

  • Semaglutide costs $249 a month, 35% above the $184 median for compounded semaglutide across the sellers we compare
  • Tirzepatide costs $299 a month, 20% above the $250 median for compounded tirzepatide across the sellers we compare
  • Confirm it serves your state before you start the intake
  • Ask which pharmacy fills the prescription before you pay, so you can check its license
  • The FDA has issued Direct Meds a warning letter. Read what it alleges: a letter flags a problem but does not by itself rule a seller out
  • Its semaglutide and tirzepatide are compounded rather than FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality

Our Verdict

Winner: Direct Meds

Direct Meds is where we would start, above all for compounded semaglutide at $249/month. altRX undercuts it by $100 a month, so if the monthly bill is what decides it, altRX is the pick. altRX fits better if semaglutide from $1149/month is your priority.

Choose altRX if…

You want semaglutide from $1149/month and an opening price near $149 a month.

Choose Direct Meds if…

You want compounded semaglutide at $249/month and an opening price near $249 a month.

Ready to start? GLP-1 providers we have vetted

Telehealth providers, vetted by us, prescribing GLP-1 online.

Vetted by our editors · no insurance required

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

9.2

He & She MD

Starting below a standard dose, with microdose tiers

5.9

Wellorithm

Compounded semaglutide at $247/month

6.6

Willow

Seeing what it charges before you answer any medical questions

altRX vs Direct Meds: FAQ

altRX. It starts at $149 a month; Direct Meds starts at $249 a month, $100 more per month.
Yes, both sell semaglutide and tirzepatide.
altRX does not publish where it ships; Direct Meds does not publish where it ships. Confirm your state before paying.
Both include the clinician visit, the medication itself and shipping.
altRX has an open FDA warning letter from June 8, 2026. Direct Meds has an open FDA warning letter from September 9, 2025.
Direct Meds pays us a commission on sign-ups through our links; altRX does not. Scores are computed the same way for both.

Or see the full category ranking.

Novo Nordisk A/S owns the Wegovy®, Ozempic® and Rybelsus® marks; Eli Lilly and Company owns Mounjaro® and Zepbound®. Every other product name and mark on this page belongs to whoever owns it. No pharmaceutical manufacturer is affiliated with GLP Watchdog. See trademark disclaimer.